Li Xuefei, Fu Yao, Yin HaiQin, Zhu Huiling
Department of Rheumatology and Immunology, Jiujiang University Affiliated Hospital, Jiujiang, Jiangxi, China.
Front Immunol. 2025 Mar 19;16:1473190. doi: 10.3389/fimmu.2025.1473190. eCollection 2025.
Immune thrombocytopenia(ITP)is a common clinical manifestation of systemic lupus erythematosus(SLE). Drug therapy includes glucocorticoids(GCs),disease-modifying anti-rheumatic drugs (DMARDs) and biologics. Refractory thrombocytopenia can be life-threatening, and the use of effective medications plays a crucial role in disease improvement. Here, we report a case of ITP secondary to SLE. The use of dexamethasone(DEX), cyclosporine A(CsA), and hetrombopag resulted in drug-induced liver injury. Subsequently, telitacicept was chosen and successfully controlled the patient's condition. It suggests that telitacicept may be a new treatment option for refractory SLE-ITP.
免疫性血小板减少症（ITP）是系统性红斑狼疮（SLE）的常见临床表现。药物治疗包括糖皮质激素（GCs）、改善病情抗风湿药（DMARDs）和生物制剂。难治性血小板减少症可能危及生命，使用有效药物对改善病情起着关键作用。在此，我们报告一例继发于SLE的ITP病例。使用地塞米松（DEX）、环孢素A（CsA）和海曲泊帕导致药物性肝损伤。随后，选择了泰它西普并成功控制了患者的病情。这表明泰它西普可能是难治性SLE-ITP的一种新的治疗选择。
